A novel sodium benzoate analog (CH-1) decreases blood ammonia levels in experimental hyperammonemia

Octavio Campollo, Ruben Cortez, Alberto M Odor, Rosa Maria Muñoz, Juan Armendariz-Borunda, Javier Alvarez-Tostado

Research output: Contribution to journalArticlepeer-review


Sodium benzoate has been used for the treatment of congenital hyperammonemic syndromes and hepatic encephalopathy for its ammonia lowering effect. A zinc-derivative of sodium benzoate (CH-1) with similar effects, is presented herein. We administered CH-1 at doses of 250, 500 and 1000 mg/kg body weight during 7 days to male Wistar rats after a portocaval shunt operation was performed as a model for experimental hyperammonemia. There was a decrease in blood ammonia levels in all groups receiving CH-1. A linear relationship (r=-0.487, P < 0.01) was observed between the dose of CH-1 and blood ammonia levels. The effective dose 50 (ED50) was 320 mg/kg body weight (95% C.I. 176-581 mg) with a slope of 1.538 (Litchfield and Wilcoxon method). These results suggest that benzoic acid salts such as CH-1 may prove a new alternative for the treatment of hyperammonemia. Potential advantages of non-sodium salts of benzoic acid are discussed.

Original languageEnglish (US)
Pages (from-to)104-109
Number of pages6
JournalHepatology Research
Issue number2
StatePublished - Jul 1999
Externally publishedYes


  • Hepatic encephalopathy
  • Hyperammonemia
  • Pharmacology
  • Sodium benzoate
  • Treatment
  • Zinc

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'A novel sodium benzoate analog (CH-1) decreases blood ammonia levels in experimental hyperammonemia'. Together they form a unique fingerprint.

Cite this